* behold related article on page 19...

* behold related article on page 1905

Shortly after the National Cancer Institute's Bethesda 2001 meeting to modify cervical cytologic terminology, (1) the American Society for Colposcopy and Cervical Pathology (ASCCP) (2) cause to growed evidence-based guidelines for the management of abnormal cervical cytologic flows These guidelines are presented in this issue of American Family Physician, (3) and a simplified algorithm-based version of the recommendations is available online at http://www.asccp.org. (4) All physicians who perform cervical cancer screening should implement these recommendations, which now are considered the standard of care. Guidelines for managing histologically confirmed cervical intraepithelial neoplasia (CIN) also were lay opened for health care providers who perform colposcopy and relevant surgical interventions. (5)

The ASCCP cytologic guidelines specifically considered management of low-grade squamous intraepithelial lesions (LSIL), high-grade squamous intraepithelial lesions (HSIL), atypical glandular small rooms (AGC), and atypical squamous lonely dwellings (ASC, subcategorized into ASC of undetermined significance [ASC-US] and ASC that cannot debar a high-grade intraepithelial lesion [ASC-H]).

Women with changes les stiff than ASC generally do not require colposcopy However, women with ASC-H or more hard results (i.e., LSIL, HSIL, AGC, cancer) should be examined through colposcopy. Postmenopausal, adolescent, and pregnant women may be managed more conservatively.

Several options are available for women with ASC-US, which may be evaluated in individual of three ways. If the Papanicolaou (Pap) exhibition was collected using liquid-based cytology, reflective testing of residual cells using a proof for 13 types of high-risk human papillomavirus (HPV) DNA is the preferr management option (Hybrid Capture 2 High-Risk HPV DNA exhibition Digene Corp., Gaithersburg, Md.). (67) Women with a positive high-risk HPV DNA ordeal result should be evaluated with colposcopy

brace important points about HPV DNA testing must be understood. First, the low-risk DNA ordeal should not be used for clinical triage of women with ASC-US. This proof is designed to detect nononcogenic HPV stamps and therefore has no utility as a triage experiment for CIN. Second, the high-risk experiment should not be used to determine by what mode cytologic abnormalities more severe than ASC-US should be managed. Because the majority of women with LSIL or more stiff cytologic changes are infected with high-risk HPV DNA marks there is no need to use the HPV DNA proof to determine if a patient is at increased risk for significant neoplasia.

Colposcopy is an acceptable management option in women with ASC-US because approximately 25 percent of these women will have a cervical neoplasia. Serially repeated Pap touchstones also are an acceptable form of follow-up in women with ASC-US. If a repeat Pap touchstone detects ASC-US or a more unadorned cytologic change, the patient should be examined from colposcopy. Serial cytologic evaluation is les robust than using a exhibition for high-risk HPV DNA or colposcopy Consequently it is questionable whether serial cytologic testing will remain an acceptable option in events to come management guidelines.

In the past, an women were monitored after colposcopy through serial cytologic testing or cytologic testing combined with colposcopy Several strange follow-up approaches are now make acceptableed In women with minor cytologic changes, barely two negative Pap test follows are required before patients can reply to a routine testing interval. Because of the more ominous nature of glandular lesions, women with AGC must have four negative follow-up cytologic example results before resuming routine Pap testing. Women with ASC-US, ASC-H, and LSIL issues and no evidence of cervical neoplasia following colposcopic examination may have repeat cytology at six and 12 month or testing for high-risk HPV DNA in 12 month The latter approach minimizes patient follow-up and allows time for regression of HPV-related lesions. Persistent HPV infection is a significant risk for the progression in a continuously ascending gradation of CIN. Because the HPV DNA exhibition has a high negative predictive value (approximately 99 percent) a negative high-risk HPV DNA touchstone result offers reassurance that the patient does not have a significant cervical neoplasia (CIN grade 3 or greater).

The management of AGC is vastly different from that of ASC. Although the one and the other diagnoses refer to "atypical" lonely dwellings women with AGC must have a more aggressive evaluation with colposcopy endocervical sampling and, in near cases, endometrial biopsy. Because of the more inaccessible nature of glandular (columnar) small cavitys within the endocervical canal and the colposcopic craft of these inconspicuous lesions, and nothing else experts should attempt to manage possible glandular neoplasia.

Additional educational information may be obtained from the ASCCP (telephone: 800-787-7227; Web site: http://www.asccp.org).

REFERENCES

(1) Solomon D Davey D Kurman R Moriarty A, O'Connor D ravage M, et al. The 2001 Bethesda System: terminology for reporting proceeds of cervical cytology. JAMA 2002;287:2114-9